Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

A new study claims that DRDO's anti-Covid drug 2-DG is effective against all Covid-19 variants.As per the study, 2-DG reduces the multiplication of SARS-CoV-2 and alleviates the cells from infection-induced cytopathic effect (CPE) and cell death. The study suggests that the drug can be used in the treatment regimen. 
Based on these preliminary in-vitro findings, the molecule is now being moved for clinical trials in Covid patients. The study, published on June 15, has not yet been peer-reviewed.
The drug, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy&rsquo;s Laboratories, received approval for emergency use in moderate to severe cases of Covid-19 in May.
Clinical trials of 2-DG found that it enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy&rsquo;s Laboratories has launched 2-DG in the form of sachets. The first batch of the oral drug was released on May 17.
Two weeks ago, DRDO issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

DRDO's anti-Covid drug 2-DG found effective against all variants, says new study

A new study claims that DRDO's anti-Covid drug 2-DG is effective against all Covid-19 variants.As per the study, 2-DG reduces the multiplication of SARS-CoV-2 and alleviates the cells from infection-induced cytopathic effect (CPE) and cell death. The study suggests that the drug can be used in the treatment regimen.
Based on these preliminary in-vitro findings, the molecule is now being moved for clinical trials in Covid patients. The study, published on June 15, has not yet been peer-reviewed.
The drug, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy&rsquo;s Laboratories, received approval for emergency use in moderate to severe cases of Covid-19 in May.
Clinical trials of 2-DG found that it enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy&rsquo;s Laboratories has launched 2-DG in the form of sachets. The first batch of the oral drug was released on May 17.
Two weeks ago, DRDO issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

DRDO's anti-Covid drug 2-DG found effective against all variants: Study New study says DRDO's anti-Covid drug 2-DG is effective against all variants Study: 2-DG reduces the multiplication of SARS-CoV-2, prevents cell death Study on DRDO's 2-DG drug clears it for use in the Covid treatment regimen Drug moved for clinical trials in Covid patients, but study not peer-viewed 2-DG got approval for emergency use in moderate to severe cases in May Clinical trials showed that drug helped in faster recovery of Covid patients Dr. Reddy&rsquo;s Laboratories launched sachets of oral drug 2-DG on May 17 DRDO has given directions on the usage of its 2-DG drug on patients Drug should be avoided for those with comorbidities, diabetes or cardiac issues ----

A new study claims that DRDO's anti-Covid drug 2-DG is effective against all Covid-19 variants.As per the study, 2-DG reduces the multiplication of SARS-CoV-2 and alleviates the cells from infection-induced cytopathic effect (CPE) and cell death. The study suggests that the drug can be used in the treatment regimen.
Based on these preliminary in-vitro findings, the molecule is now being moved for clinical trials in Covid patients. The study, published on June 15, has not yet been peer-reviewed.
The drug, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy&rsquo;s Laboratories, received approval for emergency use in moderate to severe cases of Covid-19 in May.
Clinical trials of 2-DG found that it enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy&rsquo;s Laboratories has launched 2-DG in the form of sachets. The first batch of the oral drug was released on May 17.
Two weeks ago, DRDO issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

drdo anti covid drug

Categories